How many drugs treat Infectious disease of abdomen?

Drug Landscape tracks 10 marketed treatments for Infectious disease of abdomen (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Infectious disease of abdomen?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infectious-disease-of-abdomen.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Infectious disease of abdomen — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infectious disease of abdomen (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infectious disease of abdomen, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Recarbrio	RELEBACTAM	Merck & Co.	Renal Dehydropeptidase Inhibitor [EPC]		2019-01-01
Xerava	ERAVACYCLINE DIHYDROCHLORIDE	Tetraphase Pharms			2018-01-01
Avycaz	AVIBACTAM	Cerexa Inc	beta Lactamase Inhibitor [EPC]		2015-01-01
Zerbaxa	CEFTOLOZANE	Cubist Pharms	Cephalosporin Antibacterial		2014-01-01
Doribax	DORIPENEM	Shionogi	Penem Antibacterial		2007-01-01
Tygacil	Tigecycline	Pfizer	Tetracycline	Bacterial protein synthesis	2005-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Merrem	Meropenem	Pfizer	meropenem		1996-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 12 drugs in Infectious disease of abdomen
Merck & Co. · 5 drugs in Infectious disease of abdomen
Pfizer · 5 drugs in Infectious disease of abdomen
Bristol-Myers Squibb · 4 drugs in Infectious disease of abdomen
Baxter · 3 drugs in Infectious disease of abdomen
Bayer AG · 2 drugs in Infectious disease of abdomen
Pai Holdings Pharm · 2 drugs in Infectious disease of abdomen
Generic (originally Roche) · 1 drug in Infectious disease of abdomen
Assistance Publique - Hôpitaux de Paris · 1 drug in Infectious disease of abdomen
Fresenius Kabi · 1 drug in Infectious disease of abdomen
Cubist Pharms · 1 drug in Infectious disease of abdomen
Cerexa Inc · 1 drug in Infectious disease of abdomen

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infectious disease of abdomen:

Cite this brief

Drug Landscape (2026). Infectious disease of abdomen — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infectious-disease-of-abdomen. Accessed 2026-06-10.

Infectious disease of abdomen full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing